Company Monitoring Page for Novartis

latest headlines for company on cafepharma

‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts
Fierce Pharma
Fri, 02/1/19 - 10:33 pm
Tags:
Novartis, Sandoz, layoffs, drug manufacturing
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company
Fierce Pharma
Fri, 02/1/19 - 12:00 am
Tags:
Novartis, Kymriah, CAR-T, UK, diffuse large B-cell lymphoma, Gilead Sciences
Novartis plots new course for Sandoz
BioCentury
Wed, 01/30/19 - 11:43 pm
Tags:
Novartis, Sandoz, generics
As Novartis Eyes Growth in 2019, the Company Will Likely Cut Some Prices
BioSpace
Wed, 01/30/19 - 07:05 pm
Tags:
Novartis, drug pricing, Pharma CEOs, Vas Narasimhan
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Tue, 01/29/19 - 07:21 pm
Tags:
Novartis, ICER, spinal muscular atrophy, alternative payments, drug pricing, gene therapy, Zolgensma
Pfizer, Novartis, Amgen add to 2019 drug price hikes
Biopharma Dive
Fri, 01/25/19 - 11:03 pm
Tags:
drug pricing, Pfizer, Novartis, Amgen
Novartis urges Britain to secure drug supplies before Brexit
Yahoo/Reuters
Fri, 01/25/19 - 10:16 am
Tags:
Novartis, UK, Brexit, Europe, drug shortages
3 Things You Need to Know About the FDA's Plan for Gene-Editing Drugs
Motley Fool
Sun, 01/20/19 - 10:24 pm
Tags:
FDA, gene editing, Novartis, Sarepta Therapeutics, CAR-T, Alzheimer's disease
Sandoz launches EpiPen rival at $250 per two-pack
BioPharma Dive
Fri, 01/18/19 - 09:21 pm
Tags:
Sandoz, Novartis, EpiPens, Symjepi
Novartis teams up with Oxford researchers to crunch big data into clinical insights
Endpoints
Fri, 01/18/19 - 12:05 am
Tags:
Novartis, University of Oxford, Vas Narasimhan, machine learning, artificial intelligence
Novartis CEO Who Wanted To Bring Tech Into Pharma Now Explains Why It's So Hard
Forbes
Thu, 01/17/19 - 12:04 am
Tags:
Novartis, Pharma CEOs, Vas Narasimhan, digital pharma
Massachusetts Initiative Looks at Payment Plans for Novartis' SMA Gene Therapy
BioSpace
Mon, 01/14/19 - 11:55 pm
Tags:
Massachusetts, Novartis, SMA, gene therapy, Kymriah
FDA Gives Amneal's Generic Alzheimer’s & Parkinson’s Patch a Thumbs-Up
BioSpace
Mon, 01/14/19 - 11:32 am
Tags:
FDA, Amneal, generics, Novartis, Exelon Patch, Alzheimer's disease, Parkinson's Disease
Can Botox hang with CGRP in migraine? Allergan says yes; analysts are skeptical
Fierce Pharma
Mon, 01/14/19 - 11:11 am
Tags:
Allergan, Botox, migraines, CGRP blockers, Amgen, Novartis, Aimovig, Teva Pharmaceutical, Ajovy, Eli Lilly, Emgality
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
Sun, 01/13/19 - 11:32 am
Tags:
NASH, Gilead Sciences, Merck, Roche, Novartis, Jecure Therapeutics, Pfizer, Celgene, Eli Lilly
NICE turns down Novartis' Aimovig, flagging clinical trial concerns
Biopharma Dive
Fri, 01/11/19 - 08:18 pm
Tags:
NICE, UK, Amgen, Novartis, migraines, Aimovig
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
Fri, 01/11/19 - 10:25 am
Tags:
JPMHC 2019, Merck, FDA, M&A, Celgene, Bristol-Myers Squibb, Genevant, IPOs, Eli Lilly, Novartis, GSK, Teva Pharmaceutical, Alexion, Pear Therapeutics
Novartis Defends Itself Against Kickback Allegations from Former Employee
BioSpace
Thu, 01/10/19 - 09:57 am
Tags:
Novartis, kickbacks, whistleblower lawsuits, breast cancer
Novartis puts AI on the job to help reps say the right things to the right doctors
Fierce Pharma
Wed, 01/9/19 - 07:21 pm
Tags:
Novartis, digital technology, drug reps, artificial intelligence
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
Wed, 01/9/19 - 09:40 am
Tags:
JPMHC 2019, M&A, Eli Lilly, Loxo Oncology, SAGE Therapeutics, Sanofi, Regeneron, Bristol-Myers Squibb, Celgene, Novartis, Gilead Sciences

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.